{"gene":"UBLCP1","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":2011,"finding":"UBLCP1 directly interacts with the 26S proteasome via its UBL domain, dephosphorylates proteasome subunits in vitro, inhibits proteasome activity in vitro, is exclusively localized in the nucleus, and knockdown promotes 26S proteasome assembly and selectively enhances nuclear proteasome activity.","method":"Co-immunoprecipitation, in vitro phosphatase assay, subcellular fractionation/imaging, siRNA knockdown with proteasome activity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods in single study: direct in vitro assay, UBL domain interaction mapping, nuclear localization by imaging, and KD phenotype with specific activity readout","pmids":["21949367"],"is_preprint":false},{"year":2005,"finding":"UBLCP1 contains a ubiquitin-like domain and a CTD phosphatase domain, localizes to the nucleus of COS-7 cells, and can dephosphorylate GST-CTD (RNA polymerase II C-terminal domain) in vitro.","method":"Transient transfection with microscopy for localization; in vitro phosphatase assay with GST-CTD substrate","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay and localization experiment, but single lab and partial mechanistic follow-up","pmids":["15883030"],"is_preprint":false},{"year":2013,"finding":"The UBL domain of human UBLCP1 adopts a unique structure (determined by NMR) with a distinct β3 strand and β3-α2 loop instead of the canonical β4; positively charged residues in the β3-α2 loop interact with the C-terminal leucine-rich repeat-like domain of proteasome subunit Rpn1.","method":"NMR solution structure determination; NMR interaction mapping with Rpn1 C-terminal domain","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — high-resolution NMR structure with functional interaction mapping identifying specific interface residues","pmids":["23667555"],"is_preprint":false},{"year":2019,"finding":"UBLCP1 acts as the proteasome-resident phosphatase that dephosphorylates Ser361 of Rpn1 (a 19S base subunit), antagonizing PIM1/2/3 kinase phosphorylation of this site; Rpn1-S361 phosphorylation is required for proper 26S proteasome assembly by promoting formation of a Rpn1-Rpt2 precursor complex.","method":"CRISPR/Cas9 gene editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, proteasome assembly assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including CRISPR editing, kinome screen identifying writer kinases, genetic code expansion for phosphorylation-specific reconstitution, and quantitative MS","pmids":["31843888"],"is_preprint":false},{"year":2015,"finding":"A small-molecule inhibitor (compound 13, IC50 = 1.0 µM) targeting both the UBLCP1 phosphatase active site and an adjacent binding pocket selectively inhibits UBLCP1 and, in cells, inhibits UBLCP1 function leading to upregulation of nuclear proteasome activity.","method":"Salicylic acid fragment-based library screening; enzymatic IC50 determination against phosphatase panel; cellular proteasome activity assay","journal":"Bioorganic & medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — selective inhibitor with defined active-site targeting and cellular functional readout, single lab","pmids":["25907364"],"is_preprint":false},{"year":2020,"finding":"UBLCP1, via its UBL domain, stimulates 26S proteasome peptide hydrolysis 2–5 fold and, when combined with an unfolded protein substrate, increases proteasomal ATPase activity; the UBL domain is required for the ATPase stimulation but some stimulation of peptide hydrolysis persists even without the UBL domain.","method":"In vitro proteasome activity assays (peptide hydrolysis and ATPase) with purified UBLCP1 and UBL-deleted mutants","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assays with domain-deletion mutagenesis testing both peptide hydrolysis and ATPase activities","pmids":["32071216"],"is_preprint":false},{"year":2023,"finding":"A truncating mutation in UBLCP1 exon 10 (disrupting the phosphatase domain) found in an ASD patient results in decreased UBLCP1 protein, increased proteasome activity, decreased ubiquitinated protein levels, and downregulation of proteasome subunit expression; proteasome inhibition with MG132 restores NRF1 protein levels and normalizes proteasome subunit gene expression; gentamicin read-through restores UBLCP1 expression and function.","method":"Patient-derived fibroblasts, whole exome sequencing, proteasome activity assays, MG132 pharmacological rescue, gentamicin read-through experiment","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function variant with multiple functional readouts and pharmacological rescue in patient cells, single lab","pmids":["38129378"],"is_preprint":false},{"year":2024,"finding":"UBLCP1 is enriched in cranial motor neurons (iCrMNs) relative to spinal motor neurons (iSpMNs) and identified as a cell-type-specific regulator of nuclear 26S proteasome activity in iCrMNs.","method":"Quantitative proteomics and transcriptomics of induced motor neurons; 26S vs 20S proteasome activity assays in cell subtypes","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — proteomic identification with direct 26S proteasome activity measurement distinguishing cell types, single study","pmids":["38457337"],"is_preprint":false}],"current_model":"UBLCP1 is a nuclear phosphatase that binds the 26S proteasome via its UBL domain (interacting specifically with Rpn1's leucine-rich repeat domain), dephosphorylates proteasome subunits including Rpn1-Ser361 to antagonize PIM kinase activity, and thereby inhibits 26S proteasome assembly and suppresses nuclear proteasome activity; paradoxically, UBL domain engagement also stimulates proteasomal peptide hydrolysis and ATPase activity, revealing a dual regulatory role in proteasome function."},"narrative":{"teleology":[{"year":2005,"claim":"Initial characterization established that UBLCP1 encodes a nuclear protein with a UBL domain and a CTD-type phosphatase domain capable of dephosphorylating phospho-CTD substrates in vitro, defining its basic enzymatic identity.","evidence":"Transient transfection/microscopy in COS-7 cells and in vitro phosphatase assay with GST-CTD substrate","pmids":["15883030"],"confidence":"Medium","gaps":["Physiological substrate unknown — CTD dephosphorylation may not reflect in vivo function","No connection to proteasome pathway established"]},{"year":2011,"claim":"UBLCP1 was identified as a proteasome-associated phosphatase: its UBL domain mediates binding to the 26S proteasome, it dephosphorylates proteasome subunits, and its loss selectively enhances nuclear proteasome assembly and activity, establishing its inhibitory role in proteasome regulation.","evidence":"Co-immunoprecipitation, in vitro phosphatase assay on proteasome subunits, subcellular fractionation/imaging, siRNA knockdown with proteasome activity assays","pmids":["21949367"],"confidence":"High","gaps":["Specific phospho-site substrates on the proteasome not identified","Mechanism by which dephosphorylation inhibits assembly not resolved","Identity of the opposing kinase unknown"]},{"year":2013,"claim":"Structural determination of the UBLCP1 UBL domain revealed an atypical β3-α2 loop that mediates direct interaction with the C-terminal leucine-rich repeat domain of Rpn1, pinpointing the molecular interface for proteasome recruitment.","evidence":"NMR solution structure and NMR-based interaction mapping with Rpn1 C-terminal domain","pmids":["23667555"],"confidence":"High","gaps":["Full-length UBLCP1 structure with phosphatase domain not determined","Whether additional proteasome subunits participate in the interaction unknown"]},{"year":2015,"claim":"Development of a selective small-molecule UBLCP1 inhibitor demonstrated that pharmacological blockade of UBLCP1 upregulates nuclear proteasome activity in cells, providing chemical genetic confirmation of its cellular function.","evidence":"Fragment-based library screening, IC50 determination against phosphatase panel, cellular proteasome activity assays","pmids":["25907364"],"confidence":"Medium","gaps":["Off-target effects not fully excluded","In vivo efficacy and selectivity not tested"]},{"year":2019,"claim":"Identification of Rpn1-Ser361 as the key UBLCP1 substrate resolved the phosphorylation circuit: PIM1/2/3 kinases phosphorylate Ser361 to promote Rpn1-Rpt2 precursor complex formation and 26S assembly, while UBLCP1 antagonizes this step, establishing a kinase-phosphatase regulatory axis controlling proteasome biogenesis.","evidence":"CRISPR/Cas9 editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, proteasome assembly assays","pmids":["31843888"],"confidence":"High","gaps":["Whether Rpn1-Ser361 is the sole functionally critical substrate unknown","How nuclear versus cytoplasmic pools of this phosphorylation are spatially regulated not addressed"]},{"year":2020,"claim":"Reconstituted assays revealed an unexpected stimulatory role: the UBL domain of UBLCP1 enhances 26S proteasome peptide hydrolysis and ATPase activity, demonstrating that UBLCP1 is not simply inhibitory but bifunctionally regulates proteasome function.","evidence":"In vitro proteasome peptide hydrolysis and ATPase assays with purified full-length and UBL-deleted UBLCP1","pmids":["32071216"],"confidence":"High","gaps":["How the stimulatory (UBL-mediated) and inhibitory (phosphatase-mediated) activities are coordinated in vivo is unresolved","Structural basis for UBL-driven gate opening or conformational change not determined"]},{"year":2023,"claim":"A truncating UBLCP1 mutation in a patient with autism spectrum disorder linked loss of UBLCP1 phosphatase function to increased proteasome activity, reduced ubiquitinated proteins, and NRF1-dependent downregulation of proteasome subunit expression, establishing a human disease connection.","evidence":"Patient-derived fibroblasts, whole exome sequencing, proteasome activity assays, MG132 and gentamicin pharmacological rescue","pmids":["38129378"],"confidence":"Medium","gaps":["Single patient — causality versus association not fully established","Whether proteasome dysregulation directly drives ASD-relevant neurodevelopmental phenotypes unknown","No animal model of UBLCP1 loss-of-function reported"]},{"year":2024,"claim":"Cell-type-specific enrichment of UBLCP1 in cranial motor neurons relative to spinal motor neurons correlated with differential nuclear 26S proteasome activity, suggesting a role in cell-type-specific proteasome regulation in the nervous system.","evidence":"Quantitative proteomics and transcriptomics of induced motor neurons with 26S versus 20S proteasome activity assays","pmids":["38457337"],"confidence":"Medium","gaps":["Causal role of UBLCP1 in motor neuron subtype-specific proteasome activity not demonstrated by loss-of-function","Relevance to motor neuron disease susceptibility not tested"]},{"year":null,"claim":"How UBLCP1's dual stimulatory (UBL-mediated) and inhibitory (phosphatase-mediated) activities are temporally and spatially coordinated in vivo, whether additional proteasome phospho-sites are physiologically relevant substrates, and whether UBLCP1 loss causes neurodevelopmental phenotypes in animal models remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No animal knockout model phenotyped","Full substrate spectrum on the proteasome not mapped","Structural basis for simultaneous binding and catalysis on 26S proteasome not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,5]}],"complexes":["26S proteasome"],"partners":["PSMD2","RPN1","PIM1","PIM2","PIM3"],"other_free_text":[]},"mechanistic_narrative":"UBLCP1 is a nuclear phosphatase that regulates 26S proteasome assembly and activity through dual mechanisms involving its ubiquitin-like (UBL) domain and its phosphatase domain. The UBL domain binds the leucine-rich repeat region of the proteasome subunit Rpn1, while the phosphatase domain dephosphorylates proteasome subunits including Rpn1-Ser361, antagonizing PIM kinase-mediated phosphorylation required for Rpn1-Rpt2 precursor formation and thereby inhibiting 26S proteasome assembly [PMID:21949367, PMID:31843888, PMID:23667555]. Paradoxically, UBL domain engagement stimulates proteasomal peptide hydrolysis and ATPase activity in vitro, revealing a bifunctional regulatory role [PMID:32071216]. A truncating mutation in UBLCP1 disrupting the phosphatase domain has been linked to autism spectrum disorder through increased proteasome activity and dysregulated proteasome subunit expression via the NRF1 pathway [PMID:38129378]."},"prefetch_data":{"uniprot":{"accession":"Q8WVY7","full_name":"Ubiquitin-like domain-containing CTD phosphatase 1","aliases":["Nuclear proteasome inhibitor UBLCP1"],"length_aa":318,"mass_kda":36.8,"function":"Dephosphorylates 26S nuclear proteasomes, thereby decreasing their proteolytic activity (PubMed:21949367, PubMed:28539385). Recruited to the 19S regulatory particle of the 26S proteasome through its interaction with 19S component PSMD2/RPN1 (PubMed:28539385). Once recruited, dephosphorylates 19S component PSMC2/RPT1 which impairs PSMC2 ATPase activity and disrupts 26S proteasome assembly (PubMed:28539385). Has also been reported to stimulate the proteolytic activity of the 26S proteasome (PubMed:32071216)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8WVY7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UBLCP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/UBLCP1","total_profiled":1310},"omim":[{"mim_id":"609867","title":"UBIQUITIN-LIKE DOMAIN-CONTAINING CTD PHOSPHATASE 1; UBLCP1","url":"https://www.omim.org/entry/609867"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Supported"},{"location":"Nucleoli rim","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/UBLCP1"},"hgnc":{"alias_symbol":["MGC10067","CPUB1"],"prev_symbol":[]},"alphafold":{"accession":"Q8WVY7","domains":[{"cath_id":"3.10.20.90","chopping":"4-78","consensus_level":"high","plddt":90.888,"start":4,"end":78},{"cath_id":"3.40.50.1000","chopping":"111-316","consensus_level":"high","plddt":95.532,"start":111,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WVY7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WVY7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WVY7-F1-predicted_aligned_error_v6.png","plddt_mean":90.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UBLCP1","jax_strain_url":"https://www.jax.org/strain/search?query=UBLCP1"},"sequence":{"accession":"Q8WVY7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WVY7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WVY7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WVY7"}},"corpus_meta":[{"pmid":"21949367","id":"PMC_21949367","title":"UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21949367","citation_count":65,"is_preprint":false},{"pmid":"30167433","id":"PMC_30167433","title":"Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.","date":"2018","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30167433","citation_count":60,"is_preprint":false},{"pmid":"26942285","id":"PMC_26942285","title":"A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26942285","citation_count":59,"is_preprint":false},{"pmid":"32071216","id":"PMC_32071216","title":"Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32071216","citation_count":55,"is_preprint":false},{"pmid":"24376564","id":"PMC_24376564","title":"RAPID-SELEX for RNA aptamers.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376564","citation_count":46,"is_preprint":false},{"pmid":"31843888","id":"PMC_31843888","title":"Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31843888","citation_count":46,"is_preprint":false},{"pmid":"15883030","id":"PMC_15883030","title":"Cloning and characterization of a novel RNA polymerase II C-terminal domain phosphatase.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15883030","citation_count":23,"is_preprint":false},{"pmid":"32862155","id":"PMC_32862155","title":"Human genetic background in susceptibility to tuberculosis.","date":"2020","source":"International journal of mycobacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/32862155","citation_count":21,"is_preprint":false},{"pmid":"35501893","id":"PMC_35501893","title":"Transcriptomic underpinnings of high and low mirror aggression zebrafish behaviours.","date":"2022","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/35501893","citation_count":16,"is_preprint":false},{"pmid":"29490353","id":"PMC_29490353","title":"Association of Long Noncoding RNAs Polymorphisms With Ankylosing Spondylitis, Vogt-Koyanagi-Harada Disease, and Behcet's Disease.","date":"2018","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/29490353","citation_count":13,"is_preprint":false},{"pmid":"25907364","id":"PMC_25907364","title":"A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25907364","citation_count":11,"is_preprint":false},{"pmid":"34409462","id":"PMC_34409462","title":"A transcriptome-wide association study identifies novel susceptibility genes for psoriasis.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34409462","citation_count":11,"is_preprint":false},{"pmid":"23667555","id":"PMC_23667555","title":"Solution structure and Rpn1 interaction of the UBL domain of human RNA polymerase II C-terminal domain phosphatase.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23667555","citation_count":7,"is_preprint":false},{"pmid":"35756599","id":"PMC_35756599","title":"Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline.","date":"2021","source":"Journal of psoriasis and psoriatic arthritis","url":"https://pubmed.ncbi.nlm.nih.gov/35756599","citation_count":7,"is_preprint":false},{"pmid":"38129378","id":"PMC_38129378","title":"A novel autism-associated UBLCP1 mutation impacts proteasome regulation/activity.","date":"2023","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38129378","citation_count":4,"is_preprint":false},{"pmid":"38457337","id":"PMC_38457337","title":"Identification of molecular signatures defines the differential proteostasis response in induced spinal and cranial motor neurons.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38457337","citation_count":3,"is_preprint":false},{"pmid":"40148470","id":"PMC_40148470","title":"Exploring new drug treatment targets for immune related bone diseases using a multi omics joint analysis strategy.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40148470","citation_count":3,"is_preprint":false},{"pmid":"40736211","id":"PMC_40736211","title":"Genome-wide gene by sleepiness interaction analysis for sleep apnea.","date":"2026","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/40736211","citation_count":1,"is_preprint":false},{"pmid":"40156024","id":"PMC_40156024","title":"Phosphatase UBLCP1 is required for the growth, virulence and mitochondrial integrity of Toxoplasma gondii.","date":"2025","source":"Parasites & vectors","url":"https://pubmed.ncbi.nlm.nih.gov/40156024","citation_count":0,"is_preprint":false},{"pmid":"41971766","id":"PMC_41971766","title":"Immune Cell-Mediated Retinoblastoma Development: Genetic and Molecular Mechanisms.","date":"2026","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41971766","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12556,"output_tokens":2021,"usd":0.033992},"stage2":{"model":"claude-opus-4-6","input_tokens":5317,"output_tokens":2323,"usd":0.12699},"total_usd":0.160982,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"UBLCP1 directly interacts with the 26S proteasome via its UBL domain, dephosphorylates proteasome subunits in vitro, inhibits proteasome activity in vitro, is exclusively localized in the nucleus, and knockdown promotes 26S proteasome assembly and selectively enhances nuclear proteasome activity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, subcellular fractionation/imaging, siRNA knockdown with proteasome activity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods in single study: direct in vitro assay, UBL domain interaction mapping, nuclear localization by imaging, and KD phenotype with specific activity readout\",\n      \"pmids\": [\"21949367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"UBLCP1 contains a ubiquitin-like domain and a CTD phosphatase domain, localizes to the nucleus of COS-7 cells, and can dephosphorylate GST-CTD (RNA polymerase II C-terminal domain) in vitro.\",\n      \"method\": \"Transient transfection with microscopy for localization; in vitro phosphatase assay with GST-CTD substrate\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay and localization experiment, but single lab and partial mechanistic follow-up\",\n      \"pmids\": [\"15883030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The UBL domain of human UBLCP1 adopts a unique structure (determined by NMR) with a distinct β3 strand and β3-α2 loop instead of the canonical β4; positively charged residues in the β3-α2 loop interact with the C-terminal leucine-rich repeat-like domain of proteasome subunit Rpn1.\",\n      \"method\": \"NMR solution structure determination; NMR interaction mapping with Rpn1 C-terminal domain\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution NMR structure with functional interaction mapping identifying specific interface residues\",\n      \"pmids\": [\"23667555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"UBLCP1 acts as the proteasome-resident phosphatase that dephosphorylates Ser361 of Rpn1 (a 19S base subunit), antagonizing PIM1/2/3 kinase phosphorylation of this site; Rpn1-S361 phosphorylation is required for proper 26S proteasome assembly by promoting formation of a Rpn1-Rpt2 precursor complex.\",\n      \"method\": \"CRISPR/Cas9 gene editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, proteasome assembly assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including CRISPR editing, kinome screen identifying writer kinases, genetic code expansion for phosphorylation-specific reconstitution, and quantitative MS\",\n      \"pmids\": [\"31843888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A small-molecule inhibitor (compound 13, IC50 = 1.0 µM) targeting both the UBLCP1 phosphatase active site and an adjacent binding pocket selectively inhibits UBLCP1 and, in cells, inhibits UBLCP1 function leading to upregulation of nuclear proteasome activity.\",\n      \"method\": \"Salicylic acid fragment-based library screening; enzymatic IC50 determination against phosphatase panel; cellular proteasome activity assay\",\n      \"journal\": \"Bioorganic & medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective inhibitor with defined active-site targeting and cellular functional readout, single lab\",\n      \"pmids\": [\"25907364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UBLCP1, via its UBL domain, stimulates 26S proteasome peptide hydrolysis 2–5 fold and, when combined with an unfolded protein substrate, increases proteasomal ATPase activity; the UBL domain is required for the ATPase stimulation but some stimulation of peptide hydrolysis persists even without the UBL domain.\",\n      \"method\": \"In vitro proteasome activity assays (peptide hydrolysis and ATPase) with purified UBLCP1 and UBL-deleted mutants\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assays with domain-deletion mutagenesis testing both peptide hydrolysis and ATPase activities\",\n      \"pmids\": [\"32071216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A truncating mutation in UBLCP1 exon 10 (disrupting the phosphatase domain) found in an ASD patient results in decreased UBLCP1 protein, increased proteasome activity, decreased ubiquitinated protein levels, and downregulation of proteasome subunit expression; proteasome inhibition with MG132 restores NRF1 protein levels and normalizes proteasome subunit gene expression; gentamicin read-through restores UBLCP1 expression and function.\",\n      \"method\": \"Patient-derived fibroblasts, whole exome sequencing, proteasome activity assays, MG132 pharmacological rescue, gentamicin read-through experiment\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function variant with multiple functional readouts and pharmacological rescue in patient cells, single lab\",\n      \"pmids\": [\"38129378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"UBLCP1 is enriched in cranial motor neurons (iCrMNs) relative to spinal motor neurons (iSpMNs) and identified as a cell-type-specific regulator of nuclear 26S proteasome activity in iCrMNs.\",\n      \"method\": \"Quantitative proteomics and transcriptomics of induced motor neurons; 26S vs 20S proteasome activity assays in cell subtypes\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomic identification with direct 26S proteasome activity measurement distinguishing cell types, single study\",\n      \"pmids\": [\"38457337\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UBLCP1 is a nuclear phosphatase that binds the 26S proteasome via its UBL domain (interacting specifically with Rpn1's leucine-rich repeat domain), dephosphorylates proteasome subunits including Rpn1-Ser361 to antagonize PIM kinase activity, and thereby inhibits 26S proteasome assembly and suppresses nuclear proteasome activity; paradoxically, UBL domain engagement also stimulates proteasomal peptide hydrolysis and ATPase activity, revealing a dual regulatory role in proteasome function.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"UBLCP1 is a nuclear phosphatase that regulates 26S proteasome assembly and activity through dual mechanisms involving its ubiquitin-like (UBL) domain and its phosphatase domain. The UBL domain binds the leucine-rich repeat region of the proteasome subunit Rpn1, while the phosphatase domain dephosphorylates proteasome subunits including Rpn1-Ser361, antagonizing PIM kinase-mediated phosphorylation required for Rpn1-Rpt2 precursor formation and thereby inhibiting 26S proteasome assembly [PMID:21949367, PMID:31843888, PMID:23667555]. Paradoxically, UBL domain engagement stimulates proteasomal peptide hydrolysis and ATPase activity in vitro, revealing a bifunctional regulatory role [PMID:32071216]. A truncating mutation in UBLCP1 disrupting the phosphatase domain has been linked to autism spectrum disorder through increased proteasome activity and dysregulated proteasome subunit expression via the NRF1 pathway [PMID:38129378].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Initial characterization established that UBLCP1 encodes a nuclear protein with a UBL domain and a CTD-type phosphatase domain capable of dephosphorylating phospho-CTD substrates in vitro, defining its basic enzymatic identity.\",\n      \"evidence\": \"Transient transfection/microscopy in COS-7 cells and in vitro phosphatase assay with GST-CTD substrate\",\n      \"pmids\": [\"15883030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological substrate unknown — CTD dephosphorylation may not reflect in vivo function\",\n        \"No connection to proteasome pathway established\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"UBLCP1 was identified as a proteasome-associated phosphatase: its UBL domain mediates binding to the 26S proteasome, it dephosphorylates proteasome subunits, and its loss selectively enhances nuclear proteasome assembly and activity, establishing its inhibitory role in proteasome regulation.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro phosphatase assay on proteasome subunits, subcellular fractionation/imaging, siRNA knockdown with proteasome activity assays\",\n      \"pmids\": [\"21949367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific phospho-site substrates on the proteasome not identified\",\n        \"Mechanism by which dephosphorylation inhibits assembly not resolved\",\n        \"Identity of the opposing kinase unknown\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Structural determination of the UBLCP1 UBL domain revealed an atypical β3-α2 loop that mediates direct interaction with the C-terminal leucine-rich repeat domain of Rpn1, pinpointing the molecular interface for proteasome recruitment.\",\n      \"evidence\": \"NMR solution structure and NMR-based interaction mapping with Rpn1 C-terminal domain\",\n      \"pmids\": [\"23667555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full-length UBLCP1 structure with phosphatase domain not determined\",\n        \"Whether additional proteasome subunits participate in the interaction unknown\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Development of a selective small-molecule UBLCP1 inhibitor demonstrated that pharmacological blockade of UBLCP1 upregulates nuclear proteasome activity in cells, providing chemical genetic confirmation of its cellular function.\",\n      \"evidence\": \"Fragment-based library screening, IC50 determination against phosphatase panel, cellular proteasome activity assays\",\n      \"pmids\": [\"25907364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Off-target effects not fully excluded\",\n        \"In vivo efficacy and selectivity not tested\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of Rpn1-Ser361 as the key UBLCP1 substrate resolved the phosphorylation circuit: PIM1/2/3 kinases phosphorylate Ser361 to promote Rpn1-Rpt2 precursor complex formation and 26S assembly, while UBLCP1 antagonizes this step, establishing a kinase-phosphatase regulatory axis controlling proteasome biogenesis.\",\n      \"evidence\": \"CRISPR/Cas9 editing, quantitative mass spectrometry, human kinome screen, genetic code expansion for site-specific phosphorylation, proteasome assembly assays\",\n      \"pmids\": [\"31843888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Rpn1-Ser361 is the sole functionally critical substrate unknown\",\n        \"How nuclear versus cytoplasmic pools of this phosphorylation are spatially regulated not addressed\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Reconstituted assays revealed an unexpected stimulatory role: the UBL domain of UBLCP1 enhances 26S proteasome peptide hydrolysis and ATPase activity, demonstrating that UBLCP1 is not simply inhibitory but bifunctionally regulates proteasome function.\",\n      \"evidence\": \"In vitro proteasome peptide hydrolysis and ATPase assays with purified full-length and UBL-deleted UBLCP1\",\n      \"pmids\": [\"32071216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the stimulatory (UBL-mediated) and inhibitory (phosphatase-mediated) activities are coordinated in vivo is unresolved\",\n        \"Structural basis for UBL-driven gate opening or conformational change not determined\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A truncating UBLCP1 mutation in a patient with autism spectrum disorder linked loss of UBLCP1 phosphatase function to increased proteasome activity, reduced ubiquitinated proteins, and NRF1-dependent downregulation of proteasome subunit expression, establishing a human disease connection.\",\n      \"evidence\": \"Patient-derived fibroblasts, whole exome sequencing, proteasome activity assays, MG132 and gentamicin pharmacological rescue\",\n      \"pmids\": [\"38129378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single patient — causality versus association not fully established\",\n        \"Whether proteasome dysregulation directly drives ASD-relevant neurodevelopmental phenotypes unknown\",\n        \"No animal model of UBLCP1 loss-of-function reported\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cell-type-specific enrichment of UBLCP1 in cranial motor neurons relative to spinal motor neurons correlated with differential nuclear 26S proteasome activity, suggesting a role in cell-type-specific proteasome regulation in the nervous system.\",\n      \"evidence\": \"Quantitative proteomics and transcriptomics of induced motor neurons with 26S versus 20S proteasome activity assays\",\n      \"pmids\": [\"38457337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal role of UBLCP1 in motor neuron subtype-specific proteasome activity not demonstrated by loss-of-function\",\n        \"Relevance to motor neuron disease susceptibility not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How UBLCP1's dual stimulatory (UBL-mediated) and inhibitory (phosphatase-mediated) activities are temporally and spatially coordinated in vivo, whether additional proteasome phospho-sites are physiologically relevant substrates, and whether UBLCP1 loss causes neurodevelopmental phenotypes in animal models remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No animal knockout model phenotyped\",\n        \"Full substrate spectrum on the proteasome not mapped\",\n        \"Structural basis for simultaneous binding and catalysis on 26S proteasome not resolved\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"complexes\": [\n      \"26S proteasome\"\n    ],\n    \"partners\": [\n      \"PSMD2\",\n      \"RPN1\",\n      \"PIM1\",\n      \"PIM2\",\n      \"PIM3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}